Allogeneic HSCT · 15 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
FCR Variant #07 | — | R 120 349 | 30d | ~56.4 mo | ~44.5 mo | ~5 | ~R 361 047 PFS proxy · indirect | 11 |
Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant, then allo HSCT Variant #01 Partial | — | R 27 792 | — | — | — | ~1 | ~R 27 792 indirect | — |
FBM, then allo HSCT Variant #01 Partial | — | R 27 783 | — | — | — | ~1 | ~R 27 783 indirect | — |
Cyclophosphamide and Fludarabine (FC) Variant #15 | — | R 14 005 | — | ~20.6 mo | ~37.0 mo | ~8 | ~R 112 036 PFS proxy · indirect | 4 |
TLI, then allo HSCT Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Busulfan, Fludarabine, Thiotepa Partial | — | — | — | — | — | — | — | — |
Busulfan, Fludarabine, Ibritumomab tiuxetan Partial | — | — | — | — | — | — | — | — |
Fludarabine and Melphalan Partial | — | — | — | — | — | — | — | — |
Low-dose TBI Variant #01 | — | — | — | — | — | — | — | — |
(90)YFC Partial | — | — | — | — | — | — | — | — |
Fludarabine and TBI Partial | — | — | — | — | — | — | — | — |
TFC Partial | — | — | — | — | — | — | — | — |
Busulfan and Fludarabine Partial | — | — | — | — | — | — | — | — |
Clofarabine and Melphalan Partial | — | — | — | — | — | — | — | — |
Cyclophosphamide, Fludarabine, Thiotepa Partial | — | — | — | — | — | — | — | — |
15 of 15 regimens shown